BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zedenoleucel readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Zedenoleucel\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06552416-2888@assetmemo.bio
DTSTAMP:20261121T004545Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Zedenoleucel: Phase 1 readout est. (NCT06552416)
DESCRIPTION:Zedenoleucel\, phase 1\, Acute Myeloid Leukemia.\nStudy: Safety
  of MT-401-OTS in Patients With Relapsed AML or MDS\nEstimated primary com
 pletion: September 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/zedenoleucel#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06552416
URL:https://assetmemo.bio/drug/zedenoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
